Edwards Lifesciences Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EW research report →
Range $100 – $120
Price Chart
About the company
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems.
- CEO
- Bernard J. Zovighian
- IPO
- 2000
- Employees
- 16,000
- HQ
- Irvine, CA, US
Get TickerSpark's AI analysis on EW
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $58.56B
- P/E
- 59.45
- Fwd P/E
- 33.76
- PEG
- -2.47
- P/S
- 9.07
- P/B
- 5.58
- EV/EBITDA
- 36.24
- Div Yield
- 0.00%
- Gross Margin
- 78.13%
- Op Margin
- 24.87%
- Net Margin
- 15.30%
- ROE
- 9.69%
- ROIC
- 9.09%
Latest fiscal year · YoY change
- Revenue
- $6.07B+11.5%
- Gross Profit
- $4.74B+9.7%
- Op Income
- $1.64B
- Net Income
- $1.07B-74.3%
- EPS
- $1.84-73.6%
- OCF Growth
- +194.2%
- FCF Growth
- +360.5%
- 52W High
- $108.00
- 52W Low
- $74.66
- 50D MA
- $91.87
- 200D MA
- $86.81
- Beta
- 0.83
- RSI (14)
- 67
- Avg Volume
- 3.91M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Edwards Lifesciences delivered an 11.2% sales increase in Q3, raised full-year guidance, and said TAVR and TMTT are both benefiting from stronger procedure trends, new approvals, and recent clinical evidence.· November 4, 2026
- Q3 sales were $1.72 billion, up 11.2% year over year, with adjusted EPS of $0.80.
- Management raised full-year sales growth guidance to approximately 11.5% and adjusted EPS to $2.97 to $3.05.
- TAVR sales were $1.2 billion, up 8.8%, and TMTT sales were $207 million, up 45.6%.
- Gross margin was 78.7% versus 77.9% a year ago, helped by manufacturing efficiencies and foreign exchange.
- Management said future TAVR growth should come more from procedure volume than share gains, while TMTT remains early in its growth curve.
Third quarter sales were $1.72 billion, up 11.2% year over year. Adjusted EPS was $0.80, while GAAP EPS was $0.53. Adjusted gross margin was 78.7% versus 77.9% in the prior-year quarter. TAVR sales were $1.2 billion, up 8.8%, TMTT sales were $207 million, up 45.6%, and Surgical sales were $264 million, up 3%. For full year 2026, management raised total company sales growth guidance to approximately 11.5%, TAVR growth guidance to 9% to 9.5%, TMTT sales guidance to $780 million to $790 million, and adjusted EPS guidance to $2.97 to $3.05. For Q4, the company guided to sales of $1.67 billion to $1.75 billion and adjusted EPS of $0.61 to $0.69.
Bernard Zovighian framed the quarter as broad-based outperformance across businesses and regions, supported by clinical, regulatory, and commercial milestones. He repeatedly emphasized Edwards’ long-term strategy in structural heart, saying the company is investing early to create new categories and expand access for underserved patients. His tone was confident and upbeat, especially around PROGRESS, EARLY TAVR, the updated TAVR NCD, and the expanding TMTT portfolio, which he said support durable long-term growth.
Doretta Mistras highlighted strong top-line growth and earnings leverage, noting adjusted EPS of $0.80 and adjusted operating margin of 30.3%. She said the adjusted gross margin of 78.7% was above last year’s 77.9%, with foreign exchange contributing 50 basis points of help, though she still expects full-year gross margin at the lower end of the 78% to 79% range because of currency effects through the hedging program. She also pointed to $3.1 billion of cash and cash equivalents, about $700 million of share repurchases through Q3, and $1.3 billion remaining under authorization.
Analysts focused heavily on how recent PROGRESS data, the new TAVR NCD, and asymptomatic approval could affect future TAVR growth, share gains, and the company’s 2027 outlook. Management said the impact should be gradual and more driven by market expansion than share, and that they are not signaling a slowdown; they expect more detail at the December investor conference. Questions also centered on moderate AS timing and market size, where management said the indication is a priority but declined to discuss FDA timing, while describing moderate AS as a sizable underserved opportunity. In TMTT, analysts asked about tricuspid adoption and training, and management said physicians are responding positively to PASCAL, which they view as complementary to EVOQUE.
The call pointed to multiple growth drivers working at once: stronger TAVR procedures, rapid TMTT expansion, and new clinical evidence that management believes can expand the market over time. Management also highlighted several recent approvals and evidence wins, including PROGRESS, the updated NCD, PASCAL tricuspid approval, and EVOQUE access improvements, all of which they said strengthen the long-term case for the franchise.
Management acknowledged that future TAVR growth is expected to rely more on underlying market growth than on share gains, implying share benefits may be less of a tailwind going forward. They also said the benefits from the NCD and asymptomatic indication will likely be gradual rather than immediate, and they declined to give specifics on the timing of the moderate AS filing or approval. In gross margin, FX remains a headwind, with management still expecting margins at the lower end of the full-year range.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.8%
- Shares Outstanding
- 575.00M
- Float Shares
- 568.00M
of shares held by institutions
1,379 13F filers
Buy/sell ratio 0.40. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for EW, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 1, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 13, 26 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Nov 19, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 7, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | May 12, 25 | Filing → |
| Bruce WestermanHouse · AR04 | Sell | Apr 21, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Buy | Apr 7, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Buy | Apr 8, 25 | Filing → |
| Bruce WestermanHouse · AR04 | Buy | Mar 3, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 14, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 9, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 9, 24 | Filing → |
| Markwayne MullinSenate · OK | Sell | Aug 20, 24 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 70.08M | ▼ 283.77K |
| Blackrock, Inc. | 58.79M | ▲ 6.20M |
| Vanguard Capital Management LLC | 37.62M | ▼ 111.84K |
| State Street Corp | 26.55M | ▲ 224.16K |
| Vanguard Portfolio Management LLC | 26.41M | ▲ 4.38K |
| Jpmorgan Chase & Co | 24.46M | ▲ 1.68M |
| Wellington Management Group Llp | 16.83M | ▼ 5.18M |
| Geode Capital Management, LLC | 15.61M | ▲ 168.55K |
| Dz Bank AG Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main | 13.00M | ▲ 191.06K |
| Ninety One Uk Ltd | 11.94M | ▼ 393.83K |
| Bank Of New York Mellon Corp | 11.28M | ▼ 2.80M |
| Aristotle Capital Management, LLC | 8.67M | ▲ 8.67M |
Held by 2,214 ETFs
Biggest fund positions in EW by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Dahl Andrew M. | other | 101 |
| Nov 10, 26 | Lippis Daniel J. | other | 619 |
| Nov 10, 26 | Lippis Daniel J. | sell | 619 |
| Nov 10, 26 | Lippis Daniel J. | other | 619 |
| Nov 9, 26 | Zovighian Bernard J | other | 23,100 |
| Nov 9, 26 | Zovighian Bernard J | sell | 9,184 |
| Nov 9, 26 | Zovighian Bernard J | sell | 13,916 |
| Nov 9, 26 | Zovighian Bernard J | other | 23,100 |
| Nov 9, 26 | BOBO DONALD E JR | other | 48,900 |
| Nov 9, 26 | BOBO DONALD E JR | sell | 48,900 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EW coverage
Recent articles, reports, and earnings notes.
Want a deeper read on EW?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Worried investors are paying up for these stocks — some with up to 49% upside, analysts say
marketwatch.com · Nov 18
Edwards Lifesciences Corporation $EW Stock Bought by Eurizon Capital SGR S.p.A.
defenseworld.net · Nov 15
Edwards Lifesciences Corporation $EW Stake Trimmed by Candriam S.C.A.
defenseworld.net · Nov 9
Edwards Lifesciences Q3 Earnings Call Highlights
marketbeat.com · Nov 7
Edwards Q3 Earnings & Revenues Surpass Estimates, Stock Climbs
zacks.com · Nov 5
Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Edwards Lifesciences Reports Third Quarter Results
businesswire.com · Nov 4
Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More
247wallst.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
